Follow us on Twitter
twitter icon@FreshPatents


Antibodies patents

      

This page is updated frequently with new Antibodies-related patent applications.




 Antibodies to quetiapine and use thereof patent thumbnailAntibodies to quetiapine and use thereof
Disclosed is an antibody which binds to quetiapine, which can be used to detect quetiapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of quetiapine, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone in a single lateral flow assay device..
Ortho-clinical Diagnostics, Inc.


 Peptides derived from human bplp protein, polynucleotides coding for said peptides and antibodies directed against said peptides patent thumbnailPeptides derived from human bplp protein, polynucleotides coding for said peptides and antibodies directed against said peptides
The invention relates to an in vitro method for prognosis, diagnosis or determination of the evolution of a condition involving an altered production of basic proline-rich lacrimal protein (bplp) or of any of its maturation products, by detecting, or quantifying in a biological sample of a test subject, a bplp protein or a maturation product thereof, and comparing the production of bplp protein or maturation product with the production of the same in a biological sample of a control subject. .
Institut Pasteur


 Screening for target-specific affinity binders patent thumbnailScreening for target-specific affinity binders
A method for determining the specificity of one or more antibodies, or one or more alternative affinity binders, for a target antigen can include the following steps: (i) analyzing binding of the antibody, or the alternative affinity binder, to a target antigen expressed by an antigen-expressing cell; (ii) analyzing binding of the antibody, or the alternative affinity binder, to a target antigen expressed by an equivalent antigen-expressing cell, in which cell expression of the target antigen has been silenced and/or the gene of the target antigen has been deleted; and (iii) comparing the binding reactions of the antibody, or the alternative affinity binder, in steps (i) and (ii). In various embodiments, the method further features that a reduction or loss of binding in step (ii), compared to step (i), indicates that the antibody, or the alternative affinity binder, has affinity and/or specificity for the target antigen..

 Electrochemical quantitation of autoantibodies patent thumbnailElectrochemical quantitation of autoantibodies
This disclosure describes, in one aspect, a device for electrochemical quantitation of autoantibodies. Generally, the device includes a housing that defines a plurality of channels and at least two reaction zones.
Stc.unm


 Antibodies against the muc1-c/extracellular domain (muc1-c/ecd) patent thumbnailAntibodies against the muc1-c/extracellular domain (muc1-c/ecd)
The present invention is directed to antibodies binding to muc1-c/extracellular domain (muc1-c/ecd) and methods of using such antibodies to treat cancers that express the muc1 antigen.. .
Genus Oncology, Llc


 Anti-mesothelin binding proteins patent thumbnailAnti-mesothelin binding proteins
The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies and bispecific antibodies which specifically bind to mesothelin. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies, including methods of treating and preventing cancer or other hypoproliferative disorders and related disorders by administering such antigen binding proteins and antibodies to a subject in need of such treatment..
Amgen Inc.


 Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy patent thumbnailMethods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
Methods, compositions, and kits are provided for inducing an immune response in an individual (e.g., an individual having cancer). Aspects of the methods include administering an antibody composition having an allogeneic igg antibody; and administering a treatment that activates antigen presenting cells.
The Board Of Trustees Of The Leland Stanford Junior University


 Cd37-binding molecules and immunoconjugates thereof patent thumbnailCd37-binding molecules and immunoconjugates thereof
Methods of using cd37 agents, including, but not limited to, antibodies and immunoconjugates, that bind to cd37 to deplete b-cells (e.g., non-cancerous b-cells) and methods of treating autoimmune and inflammatory diseases are further provided.. .
Immunogen, Inc.


 Compositions and methods for targeted immunomodulatory antibodies and fusion proteins patent thumbnailCompositions and methods for targeted immunomodulatory antibodies and fusion proteins
The present invention is based on the seminal discovery that targeted immunomodulatory antibodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antibodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance.
The Johns Hopkins University


 Immunomodulatory agents patent thumbnailImmunomodulatory agents
The invention provides antibodies that specifically bind to pd-l1 and fusion molecules comprising pd-l1 binding proteins constructed with an il15 receptor-binding domain, nucleic acid molecules encoding the same, and therapeutic compositions thereof. The agents inhibit pd-l1-mediated immunosuppression and enhance cell and cytokine mediated immunity for the treatment of neoplastic and infectious diseases..
Kadmon Corporation, Llc


Cancer targets and uses thereof

Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“cat”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using cat.
Celera Corporation

Anti-il-6 antibodies for the treatment of anemia

The present invention is directed to therapeutic methods using il-6 antagonists such as anti-il-6 antibodies and fragments thereof having binding specificity for il-6 to prevent or treat anemia (e.g., anemia associated with chemotherapy) including persons on a treatment regimen with a drug or chemotherapy and/or radiation for cancer (e.g., head and neck cancer) that is associated with increased risk of anemia.. .
Alderbio Holdings Llc

Antibodies to human gdf8

The present invention provides isolated human or humanized antibodies or antigen-binding fragments thereof which specifically bind to growth and differentiation factor-8 (gdf8) and block gdf8 activity. The antibodies and antibody fragments of the present invention may be used in therapeutic methods for treating conditions or disorders which are ameliorated or improved by inhibition of gdf8..
Regeneron Pharmaceuticals, Inc.

Stable protein solution formulation containing high concentration of an anti-vegf antibody

The present invention provides anti-vegf antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter.
Novartis Ag

Cartilage targeting agents and their use

Monoclonal antibodies and antibody fragments that specifically bind to matrilin-3, conjugates including these molecules, and nucleic acid molecules encoding the antibodies, antigen binding fragments and conjugates, are disclosed. Also disclosed are compositions including the disclosed antibodies, antigen binding fragments, conjugates, and nucleic acid molecules.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Means and methods for manufacturing highly pure neurotoxin

The present invention relates to an antibody which specifically binds to unprocessed and/or partially processed neurotoxin polypeptide or an antibody which specifically binds an epitope consisting of a peptide having an amino acid sequence as shown in any one of seq id nos: 1 to 16 and to methods for the manufacture of such antibodies. Moreover, the present invention relates to a composition comprising processed neurotoxin polypeptide free of unprocessed or partially processed neurotoxin polypeptide and a method for manufacturing said neurotoxin polypeptide based on the antibodies of the invention.
Merz Pharma Gmbh & Co. Kgaa

Antibodies directed against the lukgh (lukab) toxin of staphylococcus aureus and antibody sequences

The invention provides for an antibody comprising at least one binding site that specifically binds to a lukgh complex, which antibody comprises at least an antibody heavy chain variable region (vh), which comprises any of the cdr1 to cdr3 sequences as listed in table 1, or functionally active cdr variants thereof.. .
Arsanis Biosciences Gmbh

Rsv-specific antibodies and functional parts thereof

This application provides antibodies and functional equivalents thereof which are capable of specifically binding rsv, as well as means and methods for producing them.. .
Medimmune, Llc

Interleukin-10 fusion proteins and uses thereof

The present invention generally relates to fusion proteins of antibodies and interleukin-10 (il-10). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides.
Roche Glycart Ag

B7-related nucleic acids and polypeptides useful for immunomodulation

The present invention provides nucleic acids encoding b7-related factors that modulate the activation of immune or inflammatory response cells, such as t-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding b7-related polypeptides, including bsl1, bsl2, and bsl3.
Bristol-myers Sqibb Company

Mutant adeno-associated virus virions and methods of use thereof

The present invention provides mutant adeno-associated virus (aav) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant aav comprising one or more mutations in a capsid gene.
The Regents Of The University Of California

Cytotoxic tubulysin compounds for conjugation

The present invention provides one or more compounds of formula (i) for conjugation to small molecules, polymers, peptides, proteins, antibodies, antibody fragments etc.. .
Tube Pharmaceuticals Gmbh

Integrated active flux microfluidic devices and methods

The invention relates to a microfabricated device for the rapid detection of dna, proteins or other molecules associated with a particular disease. The devices and methods of the invention can be used for the simultaneous diagnosis of multiple diseases by detecting molecules (e.g.
California Institute Of Technology

Carrier-antibody compositions and methods of making and using the same

Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic..
Mayo Foundation For Medical Education And Research

Antimicrobial compositions comprising single domain antibodies and pseudomonas exotoxin

The present invention provides heavy chain immunoglobulins of the vhh type or fragment thereof having affinity for a target antigen of interest, including glycoprotein d2 (gd2) of hsv-2 or antigen thereof, and for envelope proteins of hiv-1 or an antigen thereof linked to pseudomonas exotoxin a or functional fragments thereof. Also included are multimeric forms of the immunoglobulins and their use in the prevention and/or treatment of hsv2 and/or hiv-1..
The Johns Hopkins University

Combination therapy involving antibodies against claudin 18.2 for treatment of cancer

The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing cldn18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.. .
Tron - Translationale Onkologie An Der Universitat Smedizin Der Johannes Gutenberg-universitat Mainz

Afucosylated anti-fgfr2iiib antibodies

The present invention provides antibodies that bind fgfr2iiib, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind fgfr2iiib, wherein at least 95% of the antibodies in the composition are afucosylated.
Five Prime Therapeutics, Inc.

Coronavirus proteins and antigens

Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (pedv) or porcine delta coronavirus (pdcov).
Mj Biologics, Inc.

Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Methods and compositions for enhanced cellular selectivity using nanocarrier-associated ligands

The presently disclosed subject matter provides methods and compositions for activation of clustered receptors on a target cell using nanocarrier-associated ligands, particularly methods and compositions for targeted activation of clustered receptors on antigen-experienced t cells using nanocarrier-associated antibodies.. .
The Johns Hopkins University

Carrier-antibody compositions and methods of making and using the same

Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic..
Mayo Foundation For Medical Education And Research

Biomarker and methods for early diagnosis of alzheimer's disease

A method for diagnosing of or for determining the risk of developing alzheimer's disease, as well as for determining the presence of severe ad in a subject involves at least four specific biomarkers being measured. A kit or an array comprising a detecting means, in particular antibodies, for at least four specific biomarkers can be used for the diagnosis.
Predemtec Gmbh

Biochemical markers for pulmonary and other diseases

Provided is a method of bioassay for the quantification of peptide fragments elevated in lung diseases such as copd, scc, or ipf. The peptide fragments comprise a neo-epitope formed at a cleavage site by cleavage in vivo of elastin by a proteinase.
Nordic Bioscience A/s

Anti-mif immunohistochemistry

The present invention pertains to the specific detection of mif, in particular oxmif, and of anti-oxmif antibodies in tissues. A detection method is provided which uses immunohistochemistry or immunofluorescence and wherein specific anti-oxmif antibodies and specific idiotypic monoclonal rabbit antibodies are used..
Baxalta Gmbh

Therapeutic and diagnostic methods for autism spectrum disorders and other conditions

The present invention relates to the field of autism. More specifically, the present invention provides methods for treating individuals with autism spectrum disorders.
The Johns Hopkins University

Analysis of antibodies

The present invention relates to a method which may be used for the analysis of endogenously formed antibodies such as anti-drug antibodies (adas) or rheumatoid factor (rf) in a solution, which method comprises (a) contacting the solution with a solid phase to which e.g. Igg molecule(s) have been attached; (b) allowing the adas or rf to bind specifically to the attached molecule(s); (c) adding a labeled isotype-specific reagent capable of binding adas or rf; (d) removing any excess of reagent; and (f) detecting the label bound or unbound to determine directly or indirectly the presence or concentration of adas in the solution.
Phadia Ab

Anti-uroplakin ii antibodies systems and methods

The present invention is related to the anti-uroplakin ii antibodies, kits, cocktails, and use of anti-uroplakin ii antibodies for detection of cancer.. .
Biocare Medical, Llc

Biomarker assay using microparticle aggregation

In various aspects and embodiments, the present invention is directed to versatile, label-free method for the quantitative and qualitative detection of biomarkers and/or other compounds in a fluid sample using functionalized microparticle aggregates. In these methods, micron-scale particles are functionalized to specifically interact with the biomarker being measured and added to the sample to form aggregates, the size and number of which are counted to find a volume fraction and/or number fraction of aggregates in the sample.
The University Of Akron

Method of purifying monoclonal antibodies

A new platform method to purify plant-based monoclonal antibodies is provided. Such a method includes an antibody purification platform that involves a standardized procedure for the production of a wide array of different antibodies within a simplified context.
Kentucky Bioprocessing, Inc.

Cell expansion

Embodiments are described that relate to methods and systems for growing cells in a hollow fiber bioreactor. In embodiments, the cells may be exposed to an activator for activating expansion of the cells.
Terumo Bct, Inc.

Anti-tissue factor monoclonal antibody

Monoclonal antibodies against human and mouse tissue factor, and fragments thereof, are disclosed, as well as pharmaceutical compositions and compositions for drug delivery containing the same. Therapeutic methods using the same are also disclosed..
Nanocarrier Co., Ltd.

Antibodies against claudin 18.2 useful in cancer diagnosis

The invention relates to antibodies directed against an epitope located within the c-terminal portion of cldn18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express cldn18.2.. .
Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg - Unive

Anti-fzd10 monoclonal antibodies and methods for their use

The present invention relates generally to anti-fzd10 antibodies and to methods of using anti-fzd10 antibodies. In particular, the anti-fzd10 antibodies described herein are useful for altering one or more of survival, replication, differentiation and epithelial-to-mesenchymal cell transition of embryonic stem cells and/or for the treatment of diseases, such as a variety of cancers, associated with expression of fzd10, including as stand-alone therapies and in combination therapies with other agents..
Omeros Corporation

Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody

New combined therapeutic regimens for treatment of b-cell lymphomas are disclosed which comprise, in particular, administration of anti-cd20 antibodies to patients having low-, intermediate- or high-grade non-hodgkin's lymphomas.. .
Genentech, Inc.

Multivalent antibodies

The present invention provides a multivalent antibody or a heavy/light chain component thereof comprising: a heavy chain comprising a constant region fragment, said constant region fragment located between two variable domains which are not a cognate pair, the heavy chain further comprising an fc region with at least one domain selected from ch2, ch3 and combinations thereof, with the proviso that the heavy chain contains no more than one ch1 domain and only contains two variable domains, and a light chain comprising a constant region fragment located between two variable domains which are not a cognate pair, wherein said heavy and light chains are aligned to provide a first binding site formed by a first cognate pair of variable domains and a second binding site formed by a second cognate pair of variable domains.. .
Ucb Pharma S.a.

Antibodies against tl1a and uses thereof

The disclosure provides tnf-like ligand 1a (tl1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to tl1a and inhibits interaction of tl1a and death receptor 3 (dr3) and which does not inhibit the interaction of tl1a and decoy receptor 3 (dcr3). The disclosure also provides uses of the tl1a-binding proteins..
Teva Pharmaceuticals Australia Pty Ltd

Baff selective binding compounds and related methods

The present invention relates to peptide antagonists that bind with high specificity and affinity to b-lymphocyte stimulator (“baff”), thereby antagonizing baff receptor (“baff-r”) signaling. The invention more specifically relates to vnar single chain antibodies derived from nurse shark that bind to baff, baff antagonist compounds and compositions comprising a baff specific vnar binding moiety, methods for preparing them, diagnostic and therapeutic methods of use relating to in vitro or in vivo b cell depletion, e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to kill or deplete b cells, such as in autoimmune diseases including systemic lupus erythematosus (sle), rheumatoid arthritis (ra) or multiple sclerosis (ms), and in certain hematological cancers, including lymphomas, leukemias and myelomas..
Ossianix, Inc.

Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and related therapies

Improved anti-cd154 antibodies are provided herein which have ablated fcr binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein..
The Trustees Of Dartmouth College

Methods of treating cancer with antibodies that target the insulin-like growth factor type i receptor (igf-1r)

The present invention provides compositions and methods of use of anti-igf-1r antibodies or antibody fragments. Preferably the antibodies bind to igf-1r but not ir; are not agonists for igf-1r; do not block binding of igf-1 or igf-2 to isolated igf-1r, but effectively neutralize activation of igf-1r by igf-1 in intact cells; and block binding of an r1 antibody to igf-1r.
Immunomedics, Inc.

Antibodies against canine pd-1

The present invention discloses antibodies to canine pd-1 that have specific sequences and a high binding affinity for canine pd-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs..
Intervet Inc.

Humanized or chimeric cd3 antibodies

The present invention relates to humanized or chimeric antibodies binding cd3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment..
Genmab A/s

Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish

The present invention relates to a new generation of chimeric antigen receptors (car), under single-chain or multi-chain forms, the specificity of which, to a desired antigen, is conferred by a vnar polypeptide derived from monomeric antibodies from cartilaginous fish. Such cars, which aim to redirect immune cell specificity toward selected undesired malignant cells, are compact and thus particularly adapted to target hollow antigens such as ions channels of efflux pumps present at the surface of drug-resistant cells.
Cellectis

Therapeutic pharmaceutical composition employing anti-slc6a6 antibody

The present invention aims to provide a pharmaceutical composition for cancer treatment, which comprises a novel monoclonal antibody binding to slc6a6 or its extracellular region and a chemotherapeutic agent conjugated therewith, as well as a therapeutic method in which the monoclonal antibody or a therapeutic agent composed of the monoclonal antibody conjugated with a chemotherapeutic agent is used in combination with a chemotherapeutic agent. The present invention provides a pharmaceutical composition comprising an antibody conjugate configured such that a monoclonal antibody having higher affinity than conventional antibodies and recognizing native slc6a6 or a native polypeptide of an extracellular region of slc6a6 is conjugated with an anticancer agent or the like having activity against cancer and other hyperproliferative diseases..
Order-made Medical Research Inc.

Anti-il-23 antibodies

The present invention relates to anti-il-23p19 binding compounds, in particular new humanized anti-il-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same.. .
Boehringer Ingelheim International Gmbh

Antibodies directed against interleukin-33 (il-33)

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (il-33). The invention provides an il-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide.
Anaptysbio,inc.

Antigenic gm-csf peptides and antibodies to gm-csf

Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided.
Morphotek, Inc.

Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors

A method of treating patients suffering from cancers driven by deregulated human epidermal growth factor receptor (her1/human egfr) comprising administering to a patient in need of such treatment a flexible and active regimen for combining a tyrosine kinase inhibitor (tki) and anti-egf antibodies for inhibition of the pathway activated by egf-egfr binding (mab). The anti-egf antibodies can be produced by active immunization or provided passively by the administration of antibodies that are anti-egf.
Bioven 3 Limited

Antigen binding proteins

The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid p component (sap), polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, alzheimer's disease, and type 2 diabetes..
Glaxo Group Limited

Anti-p40 antibodies systems and methods

The present invention is related to the anti-p40 antibodies, kits, cocktails, and use of anti-p40 antibodies for detection of cancer.. .
Biocare Medical, Llc

Methods and compositions for modulation of olfml3 mediated angiogenesis

The present invention relates to antibodies against specific domains of olfml3 and the use of such in angiogenesis. In particular aspects, angiogenesis-related conditions, such as cancer, can be treated by the composition comprising the olfml3 antagonists..
Research Development Foundation

Aglycosylated anti-bb antibodies and uses thereof

An aglycosylated humanized anti-bb (aafbb) antibody or antigen binding fragment thereof includes a modification at a conserved n-linked site in the ch2 domains of an fc portion of the antibody or antigen binding fragment thereof.. .
Novelmed Therapeutics, Inc.

Aglycosylated anti-c3b antibodies and uses thereof

An aglycosylated humanized anti-c3b (aac3b) antibody or antigen binding fragment thereof includes a modification at a conserved n-linked site in the ch2 domains of an fc portion of the antibody or antigen binding fragment thereof.. .
Novelmed Therapeutics, Inc.

Human igm antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system

antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof.

Neutralizing gp41 antibodies and their use

Monoclonal neutralizing antibodies are disclosed that specifically bind to the hiv-1 gp41 membrane-proximal external region (mper). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Antibodies specific for enteroviruses that infect humans

This invention provides antibodies or fragments thereof that are capable of specifically binding to at least one conformational epitope of enterovirus 71 (ev71), wherein the antibody individually comprises at least one variable light chain and at least one variable heavy chain. There is also provided a method of producing an antibody capable of specifically binding to at least one conformational epitope of enterovirus 71 (ev71)..
Mab Explorations Sdn Bhd

Hiv-1 v3 mimotopes capable of inducing cross-clade neutralizing antibodies

The invention provides methods, compositions and kits for treating and or preventing an hiv infection. For example, hiv envelope-like polypeptides (wild-type hiv polypeptides and mimotopes) may be administered to an individual so as to induce a protective immune response to hiv.
Dana-farber Cancer Institute

Radioligands for pretargeted pet imaging and methods of their therapeutic use

Described herein are tz/tco-based pretargeting strategies using an al[18f]-nota-labeled tetrazine radioligand. This imaging strategy enables delineation of cancer at earlier time points compared to other imaging strategies and further decreases the radiation dose to healthy tissues compared to directly labeled antibodies.
Memorial Sloan Kettering Cancer Center

Enzymatic conjugation of polypeptides

The present application relates to methods for the enzymatic functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions..
Paul Scherrer Institut

Novel vaccines against hpv and hpv-related diseases

Embodiments relate to novel vaccines against human papillomavirus (hpv) and hpv-related diseases, including multiple types of cancers. The hpv vaccines are composed of anti-human dendritic cell (dc) surface receptor antibodies, including cd40, and e6/7 proteins of hpv 16 and 18.
Baylor Research Institute

Immunogenicity assay

Assays for detecting antibodies to pharmaceutical preparations, food allergens and environmental allergens are described.. .
Anp Technologies, Inc.

Devices and methods for detecting amniotic fluid in vaginal secretions

The present invention relates to a diagnostic method for the detection of small quantities of amniotic fluid in the vagina. More specifically, the invention relates to the detection of pamg-1 in the vagina using anti-pamg-1 antibodies..
N-dia, Inc.

Diagnostic biomarkers and therapeutic targets for pancreatic cancer

We identified >40 proteins that elicited at least a 2-fold increase in antibody response post-pancreatic-cancer vaccination, from each of three patients' sera. The antibody responses detected against these proteins in patients with >3 years disease-free survival indicates the anti-tumor potential of targeting these proteins.
The Johns Hopkins University

Biomarker and uses thereof

The invention relates to a method of determining the inflammatory disorder status of a subject comprising detecting the presence or absence, or the level, of (i) citrullinated tenascin-c and/or one or more fragments of citrullinated tenascin-c; and/or (ii) autoantibodies with specificity for citrullinated tenascin-c and/or one or more fragments of citrullinated tenascin-c, in a sample from said subject.. .
Isis Innovation Limited

Phospholipases, nucleic acids encoding them and methods for making and using them

In alternative embodiments, the invention provides phosphatidylinositol-specific phospholipase c (pi-plc) enzymes, nucleic acids encoding them, antibodies that bind specifically to them, and methods for making and using them. Industrial methods and products comprising use of these phospholipases are also provided.
Dsm Ip Assets B.v.

Chemically-locked bispecific antibodies

There is disclosed a process for forming chemically-locked bispecific or heterodimer antibodies, preferably in the igg class, in high specificity and with high homogeneity. More specifically, there is disclosed a chemically-locked bispecific igg class antibody having a linkage region joined together with bio-orthogonal click chemistry..
Sorrento Therapeutics, Inc.

Antibody therapeutics that bind psma

There is disclosed compositions and methods relating to or derived from anti-psma antibodies. More specifically, there is disclosed fully human antibodies that bind psma, psma-antibody binding fragments and derivatives of such antibodies, and psma-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.

Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.. .
Precision Biologics, Inc.

Frizzled-binding agents and uses thereof

Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified.
Oncomed Pharmaceuticals, Inc.

Cd37-binding molecules and immunoconjugates thereof

Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to cd37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided..
Immunogen, Inc.

Recombinant obligate anaerobic gram-positive bacteria (as amended)

An object of the present invention is to effectively induce cancer cell apoptosis using the anti-trail-r1 antibody(ies) and the anti-trail-r2 antibody(ies) and to reduce the toxicity imposed on normal cells. The present invention relates to recombinant obligate anaerobic gram-positive bacteria that include a nucleic acid encoding a fusion protein having 3 or more anti-trail-r1 single-chain antibodies and/or 3 or more anti-trail-r2 single-chain antibodies, in an expressible state..
Teikyo Heisei University

Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)

Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis..
Five Prime Therapeutics, Inc.

Bi-specific cd3 and cd19 antigen-binding constructs

Antigen-binding constructs, e.g., antibodies, which bind cd3 and cd 19 and methods of use are disclosed.. .
Zymeworks Inc.

Anti-lag-3 antibodies to treat hematological malignancies

Provided are methods for clinical treatment of hematological malignancies, such as relapsed or refractory chronic lymphocytic leukemia or lymphoma using an anti-lag-3 antibody. Particular malignancies include, e.g., chronic lymphocytic leukemia (cll), hodgkin lymphoma (hl), or non-hodgkin lymphoma (nhl)..
Bristol-myers Squibb Company

Frizzled receptor antibodies for treatment of cancer

The invention provides antibodies or an antigen-binding portion thereof, which recognize the human frizzled 7 receptor. Further, the invention provides methods of using these antibodies for the treatment cancer in a subject..
Tel Hashomer Medical Research Infrastructure And Services Ltd.

Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers

Methods and compositions for treating hemophagocytic lymphohistiocytosis (hlh) are provided. The disclosure also relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of cxcl9, elevated levels of total ifnγ, and other biomarkers.
Novimmune Sa

Use of il-1 beta binding antibodies for treating peripheral arterial disease

The present invention relates to a method for treating or alleviating the symptoms of peripheral arterial disease (pad) in a subject, comprising administering about 25 mg to about 300 mg of an il-1β binding antibody or functional fragment thereof.. .
Novartis Ag

Tnfa-il-17 bispecific antibodies

Bispecific tetravalent antibodies against il-17 and tnfa, useful in therapy, e.g. The treatment of rheumatoid arthritis and other autoimmune diseases and/or to reduce pathological inflammatory conditions..
Hoffmann-la Roche Inc.

Composition and the diagnosis and treatment of diseases associated with neurite degeneration

Provided herein are antibodies and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.. .
Abbvie Inc.

Novel human genes relating to respiratory diseases and obesity

This invention relates to isolated nucleic acids comprising genes of human chromosome 12q23-qter and the proteins encoded by these genes. Expression vectors and host cells containing such genes or fragments thereof, as well as antibodies to the proteins encoded by these nucleic acids are also included herein..
Oscient Pharmaceuticals Corporation

Abeta conformer selective anti-abeta globulomer monoclonal antibodies

The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of alzheimer's disease. In particular, the present invention relates to monoclonal antibodies referred to as 10f4 and 3c5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto..
Abbvie Deutschland Gmbh & Co. Kg

N antibody possessing an affinity for epithelial secretory and nervous tissue, as well as tumour tissue derived from these tissues as well as the use thereof

We disclose the use of bacterial antigens and obtained antibodies. The resulting antibodies can be used in the diagnosis of tumors by immunohistochemistry and in the binding of drugs to antibodies for use in cancer therapy..
Uniwersytet Medyczny Im. PiastÓw Slaskich We Wrocl Wroclawiu

Monoclonal antibody cocktails for treatment of ebola infections

Antibody variants originating from the monoclonal antibody 13c6, and wherein the n-glycosylation site within the constant region of the heavy chain contains a glycan that is either wild-type or largely devoid of fucose residues, will bind ebola virus glycoprotein and provide surprising efficacy in treating animals or humans infected with ebola virus when used in combination with one or more additional anti-ebola mabs. Such antibody cocktails are vastly superior to other known monoclonal antibodies or monoclonal antibody combinations in treating animals and humans infected with the ebola virus..

Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen

The invention is in the field of medical treatment and prevention. The invention provides an antibody or a part thereof capable of specifically binding to the hepatitis b surface antigen (hbsag) and having hepatitis b virus (hbv) neutralizing activity, wherein said antibody or fragment thereof comprises a light chain cdr1 region comprising the amino acid sequence of seq id no: 5, a light chain cdr2 region comprising the amino acid sequence of seq id no: 6, a light chain cdr3 region comprising the amino acid sequence of seq id no: 7, a heavy chain cdr1 region comprising the amino acid sequence of seq id no: 8, a heavy chain cdr2 region comprising the amino acid sequence of seq id no: 9 and a heavy chain cdr3 region comprising the amino acid sequence of seq id no: 10..

Inhibition of il-17 production

The invention concerns inhibition of the production of proinflammatory cytokine interleukin-17 (il-17) by t cells, using an antagonist of interleukin-23 (il-23). The invention further concerns the use of il-23 antagonists in the treatment of inflammatory diseases characterized by the presence of elevated levels of il-17.
Genentech, Inc.



Antibodies topics:
  • Antibodies
  • Recombinant
  • Nucleic Acid
  • Nucleic Acids
  • Polypeptide
  • Therapeutics
  • Immunoglobulin
  • Immunoglobulins
  • Monoclonal
  • Radiation Therapy
  • Desmoplastic
  • Hypertension
  • Hypertensive
  • Immunotherapy
  • Photodynamic Therapy


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Antibodies for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antibodies with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.835

    file did exist - 4757

    2 - 1 - 102